OptiBiotix Health PLC Directorate Changes (1283B)

TIDMOPTI

RNS Number : 1283B

OptiBiotix Health PLC

08 January 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Directorate changes

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announces that further to the announcement dated 5 December 2017, Richard Colin Neil Davidson CBE has been appointed as Non-Executive Chairman to the Company. Simultaneous with Mr Davidson's appointment, Adam Reynolds, as previously disclosed, has stepped down as a director of the Company.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Richard Colin Neil Davidson CBE (aged 66):

 
 Current Appointments       Appointments in the last 
                             5 years 
 Bridge4 Health Limited     Competition Law Process 
                             Management Limited 
 Bridge4 Rehabilitation     Eminate Limited 
  Limited 
 Cricketarchive Limited     Maplewell Limited 
 Eclipse Film Partners      Persimmon Plc 
  No.38 LLP 
 Foodzeen Limited           Produce Investments Plc 
 T S Bloor & Sons Limited   Television Nottingham 
                             Limited 
 Testmatchextra.com 
  Limited 
 The Cricketer Publishing 
  Limited 
 Thixate Limited 
 United Church Schools 
  Foundation Limited 
 United Learning Trust 
 WM Morrison Supermarkets 
  Plc 
 Wireframe IO Limited 
 

There is no information regarding Mr Davidson required to be disclosed under the AIM Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                                                  www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                               Contact via 
                                                                            Walbrook below 
 
 Cairn Financial Advisers LLP                                                Tel: [phone] 
                                                                                      0880 
 Liam Murray / Jo Turner 
 
 finnCap Broker                                                              Tel: [phone] 
                                                                                      0500 
 Adrian Hargrave / Scott Mathieson 
  / Kate Bannatyne (Corporate Finance) 
 Tony Quirke (Corporate Broking) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Anna Dunphy                                                                Mob: [phone] 
                                                                                       001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOABXGDBUSGBGIU

(END) Dow Jones Newswires

January 08, 2018 02:00 ET (07:00 GMT)